<p>Bioventus Inc.（纽约证券交易所代码：BVS - 获取免费报告）董事 Guy Nohra 于 12 月 4 日星期四出售了 10,000 股公司的股票。股票以平均价格 7.57 美元出售，总交易额为 75,700.00 美元。出售后，该董事持有 116,610 股公司的股票，价值约为 882,737.70 美元。这代表其持股比例减少了 7.90%。该交易已在向 SEC 提交的法律文件中披露，文件可通过此链接获取。</p>
<h2>Bioventus 股票表现</h2>
<p>BVS 的股票在周一交易时段上涨 0.10 美元，达到 7.19 美元。该股票的交易量为 277,376 股，而其平均交易量为 374,594 股。Bioventus Inc.的 12 个月最低价为 5.81 美元，最高价为 11.85 美元。该公司的市值为 5.9507 亿美元，市盈率为-11.79，贝塔值为 0.79。公司的债务与股本比率为 1.85，流动比率为 1.41，速动比率为 0.99。该股票的 50 日移动平均价格为 7.08 美元，200 日移动平均价格为 6.93 美元。</p>
<h2>对 Bioventus 的对冲基金看法</h2>
<p>机构投资者最近买入和卖出了该股票的股份。Russell Investments Group Ltd.在第一季度将其在 Bioventus 的股份提高了 23,761.5%。Russell Investments Group Ltd.现在拥有 6,204 股公司的股票，价值 57,000 美元，此前在上个季度又购买了 6,178 股。Covestor Ltd 在第三季度将其在 Bioventus 的股份提高了 28.0%。Covestor Ltd 现在拥有 9,951 股公司的股票，价值 67,000 美元，此前在上个季度又购买了 2,176 股。PharVision Advisers LLC 在第二季度购买了 Bioventus 的新股份，价值 67,000 美元。HB Wealth Management LLC 在第三季度购买了 Bioventus 的新职位，价值约 72,000 美元。最后，Fox Run Management L.L.C.在第二季度获得了 Bioventus 的新职位，价值 72,000 美元。62.94% 的股票由机构投资者持有。</p>
<h2>Bioventus 公司简介</h2>
<p>（获取免费报告）</p>
<p>Bioventus Inc 是一家医疗设备公司，专注于开发和商业化治疗方法，以促进和增强身体的自然愈合过程，业务遍及美国及国际市场。公司的产品组合包括疼痛治疗，涵盖非手术疼痛注射疗法，以及外周神经刺激产品，如 Durolane、GELSYN-3 和 SUPARTZ，用于治疗膝关节骨关节炎，以及 Stimrouter 用于治疗慢性外周疼痛。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Bioventus 更好</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
<li>投资组合提升的三只最佳金融科技股票</li>
<li>内部人士正在出售的五只科技股票（但聪明的投资者正在加仓）</li>
<li>什么是微型股？您需要知道的一切</li>
<li>为什么 FuelCell Energy 的股票在政府交易后飙升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJWUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元在 Bioventus 吗？</h2>
<p>在您考虑 Bioventus 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bioventus 并不在名单上。</p>
<p>虽然 Bioventus 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Bioventus Inc. 董事 Guy Nohra 出售了 10,000 股，交易金额为 75,700 美元，减少了 7.90% 的持股比例。出售后，他持有 116,610 股，价值 882,737.70 美元。该交易已在 SEC 文件中披露。Bioventus 股票交易价格为 7.19 美元，市值为 5.9507 亿美元。机构投资者持有 62.94% 的股份。Bioventus 开发用于疼痛治疗的医疗设备</p>

<p>Bioventus Inc. (NYSE:BVS - Get Free Report) Director Guy Nohra sold 10,000 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $7.57, for a total transaction of $75,700.00. Following the sale, the director owned 116,610 shares of the company's stock, valued at approximately $882,737.70. This represents a 7.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.</p>
<div class="lb-trans"><p>Bioventus Inc.（纽约证券交易所代码：BVS - 获取免费报告）董事 Guy Nohra 于 12 月 4 日星期四出售了 10,000 股公司的股票。股票以平均价格 7.57 美元出售，总交易额为 75,700.00 美元。出售后，该董事持有 116,610 股公司的股票，价值约为 882,737.70 美元。这代表其持股比例减少了 7.90%。该交易已在向 SEC 提交的法律文件中披露，文件可通过此链接获取。</p>
</div><h2>Bioventus Stock Performance</h2>
<div class="lb-trans"><h2>Bioventus 股票表现</h2>
</div><p>Shares of BVS traded up $0.10 during trading hours on Monday, hitting $7.19. The stock had a trading volume of 277,376 shares, compared to its average volume of 374,594. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $11.85. The firm has a market capitalization of $595.07 million, a PE ratio of -11.79 and a beta of 0.79. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a fifty day moving average price of $7.08 and a 200 day moving average price of $6.93.</p>
<div class="lb-trans"><p>BVS 的股票在周一交易时段上涨 0.10 美元，达到 7.19 美元。该股票的交易量为 277,376 股，而其平均交易量为 374,594 股。Bioventus Inc.的 12 个月最低价为 5.81 美元，最高价为 11.85 美元。该公司的市值为 5.9507 亿美元，市盈率为-11.79，贝塔值为 0.79。公司的债务与股本比率为 1.85，流动比率为 1.41，速动比率为 0.99。该股票的 50 日移动平均价格为 7.08 美元，200 日移动平均价格为 6.93 美元。</p>
</div><h2>Hedge Funds Weigh In On Bioventus</h2>
<div class="lb-trans"><h2>对 Bioventus 的对冲基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its stake in shares of Bioventus by 23,761.5% during the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company's stock worth $57,000 after acquiring an additional 6,178 shares during the last quarter. Covestor Ltd lifted its stake in shares of Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company's stock worth $67,000 after purchasing an additional 2,176 shares during the last quarter. PharVision Advisers LLC purchased a new stake in shares of Bioventus during the 2nd quarter valued at $67,000. HB Wealth Management LLC purchased a new position in shares of Bioventus in the 3rd quarter valued at approximately $72,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Bioventus in the 2nd quarter valued at $72,000. 62.94% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该股票的股份。Russell Investments Group Ltd.在第一季度将其在 Bioventus 的股份提高了 23,761.5%。Russell Investments Group Ltd.现在拥有 6,204 股公司的股票，价值 57,000 美元，此前在上个季度又购买了 6,178 股。Covestor Ltd 在第三季度将其在 Bioventus 的股份提高了 28.0%。Covestor Ltd 现在拥有 9,951 股公司的股票，价值 67,000 美元，此前在上个季度又购买了 2,176 股。PharVision Advisers LLC 在第二季度购买了 Bioventus 的新股份，价值 67,000 美元。HB Wealth Management LLC 在第三季度购买了 Bioventus 的新职位，价值约 72,000 美元。最后，Fox Run Management L.L.C.在第二季度获得了 Bioventus 的新职位，价值 72,000 美元。62.94% 的股票由机构投资者持有。</p>
</div><h2>Bioventus Company Profile</h2>
<div class="lb-trans"><h2>Bioventus 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.</p>
<div class="lb-trans"><p>Bioventus Inc 是一家医疗设备公司，专注于开发和商业化治疗方法，以促进和增强身体的自然愈合过程，业务遍及美国及国际市场。公司的产品组合包括疼痛治疗，涵盖非手术疼痛注射疗法，以及外周神经刺激产品，如 Durolane、GELSYN-3 和 SUPARTZ，用于治疗膝关节骨关节炎，以及 Stimrouter 用于治疗慢性外周疼痛。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Bioventus</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)</li>
<li>What is a Microcap Stock? Everything You Need to Know</li>
<li>Why FuelCell Energy Stock Is Soaring After a Government Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Bioventus 更好</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
<li>投资组合提升的三只最佳金融科技股票</li>
<li>内部人士正在出售的五只科技股票（但聪明的投资者正在加仓）</li>
<li>什么是微型股？您需要知道的一切</li>
<li>为什么 FuelCell Energy 的股票在政府交易后飙升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJWUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=BVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bioventus Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Bioventus 吗？</h2>
</div><p>Before you consider Bioventus, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Bioventus 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bioventus 并不在名单上。</p>
</div><p>While Bioventus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bioventus 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bioventus (NYSE:BVS) 的一位董事出售了价值 75,700.00 美元的股票